

agree with Dr. Astrup that lidocaine is a "good drug," but we want to emphasize that it may have detrimental effects in some situations.

LESLIE NEWBERG MILDE, M.D.  
*Assistant Professor of Anesthesiology*

JAMES H. MILDE  
*Instructor in Anesthesiology  
Department of Anesthesiology  
Mayo Clinic  
Rochester, Minnesota 55905*

#### REFERENCES

1. Michenfelder JD, Messick JM, Jr, Theye RA: Simultaneous cerebral blood flow measured by direct and indirect methods. *J Surg Res* 8:475-481, 1968
2. Artru AA, Michenfelder JD: Effects of hypercarbia on canine cerebral metabolism and blood flow with simultaneous direct and indirect measurement of blood flow. *ANESTHESIOLOGY* 52:466-469, 1980
3. Michenfelder JD, Theye RA: Hypothermia: Effect on canine brain and whole-body metabolism. *ANESTHESIOLOGY* 29:1107-1112, 1968
4. Milde LN, Milde JH: The detrimental effect of lidocaine on cerebral metabolism measured in dogs anesthetized with isoflurane. *ANESTHESIOLOGY* 67:180-184, 1987
5. Newberg LA, Milde JH, Michenfelder JD: The cerebral metabolic effects of isoflurane at and above concentrations that suppress cortical electrical activity. *ANESTHESIOLOGY* 59:23-28, 1983
6. Newberg LA, Milde JH, Michenfelder JD: Systemic and cerebral effects of isoflurane-induced hypotension in dogs. *ANESTHESIOLOGY* 60:541-546, 1984
7. Van Aken H, Brussel T, Fitch W, Hauss GM, Graham D: Hypotension induced by isoflurane. Its effect on blood flow and cerebral autoregulation. *Cah Anesthesiol* 34:47-53, 1986
8. Newberg LA, Milde JH, Michenfelder JD: Cerebral and systemic effects of hypotension induced by adenosine or ATP in dogs. *ANESTHESIOLOGY* 62:429-436, 1985
9. ROALD OK, STEEN PA, STANGLAND K, MICHENFELDER JD: The effects of triazolam on cerebral blood flow and metabolism in the dog. *Acta Anaesthesiol Scand* 30:223-226, 1986
10. Roald OK, Steen PA, Milde JH, Michenfelder JD: Reversal of the cerebral effects of diazepam in the dog by the benzodiazepine antagonist Ro 15-1788. *Acta Anaesthesiol Scand* 30:341-345, 1986
11. Kramer RS, Sanders AP, Lesage AM, Woodhall B, Sealy WC: The effect of profound hypothermia on preservation of cerebral ATP content during circulatory arrest. *J Thorac Cardiovasc Surg* 56:699-709, 1968
12. Folkbergrova J, MacMillan V, Siesjo BK: The effect of moderate and marked hypercapnia upon the energy state and upon the cytoplasmic NAD/NADH+ ratio of the rat brain. *J Neurochem* 19:2497-2517, 1972
13. Lowry OH, Passoneau JV, Hasselberger FX, Shultz DW: Effect of ischemia on known substrates and cofactors of the glycolytic pathway in brain. *J Biol Chem* 239:18-30, 1964
14. Milde LN, Milde JH, Michenfelder JD: The cerebral functional, metabolic, and hemodynamic effects of etomidate in dogs. *ANESTHESIOLOGY* 63:371-377, 1985
15. Milde LN, Milde JH: The cerebral hemodynamic and metabolic effects of sufentanil in dogs (abstract). *ANESTHESIOLOGY* 67:A570, 1987
16. Newberg LA, Michenfelder JD: Cerebral protection by isoflurane during hypoxemia or ischemia. *ANESTHESIOLOGY* 59:29-35, 1983
17. Steen PA, Newberg LA, Milde JH, Michenfelder JD: Nimodipine improves cerebral blood flow and neurologic recovery after complete cerebral ischemia in the dog. *J Cereb Blood Flow Metab* 3:38-43, 1983
18. Steen PA, Newberg LA, Milde JH, Michenfelder JD: Cerebral blood flow and neurologic outcome when nimodipine is given after complete cerebral ischemia in the dog. *J Cereb Blood Flow Metab* 4:82-87, 1984
19. Newberg LA, Steen PA, Milde JH, Michenfelder JD: Failure of flunarizine to improve cerebral blood flow or neurologic recovery in a canine model of complete cerebral ischemia. *Stroke* 15:666-669, 1984
20. Milde LN, Milde JH, Michenfelder JD: Delayed treatment with nimodipine improves cerebral blood flow after complete cerebral ischemia in the dog. *J Cereb Blood Flow Metab* 6:332-337, 1986
21. Hascke RH, Fink BR: Lidocaine effects on brain mitochondrial metabolism *in vitro*. *ANESTHESIOLOGY* 42:737-740, 1975

(Accepted for publication November 4, 1987.)

### Differences in the Response of Humans and Dogs to Succinylcholine

*To the Editor:*—We were interested to read Professor Merin's comments on the duration of action of succinylcholine (SDC) in dogs compared with humans.<sup>1</sup> Our findings indicate strongly that the prolonged relaxation experienced by dogs when treated with SDC, in a dose which would be appropriate for a human, can be attributed to differences between canine and human cholinesterase.

We measured plasma cholinesterase activity in 14 dogs of different breeds and both sexes. For each animal, we performed four measurements using as substrates propionylthiocholine,<sup>2</sup> from which thiocholine is released and coupled with 5-5' dithiobis (2 nitrobenzoic acid) (DTNB); butyrylthiocholine,<sup>3</sup> again utilizing DTNB; benzoyl choline,<sup>4</sup> relying on its absorption at 240 nm; and SDC,<sup>5</sup> measuring choline by use of choline

TABLE 1. A Comparison of Cholinesterase Activities in Dogs and Humans ( $\pm 1$  SD) Measured Using Four Substrates. Figures in Parentheses Represent the Mean Activity in Dogs Expressed as a Percentage of that for Humans Using the Same Substrate

Substrate	Propionyl Thiocholine IU/ml	Butyryl Thiocholine IU/ml	Benzoylcholine IU/ml	Succinylcholine IU/l
Humans N = 117	4.58 $\pm$ 1.16	5.04 $\pm$ 1.27	0.88 $\pm$ 0.25	58.5 $\pm$ 11.75*
Dogs N = 14	2.33 $\pm$ 0.94 (48.7%) $P < 0.001$ †	2.33 $\pm$ 0.47 (46.2%) $P < 0.001$ †	0.36 $\pm$ 0.046 (40.1%) $P < 0.001$ †	8.6 $\pm$ 4.3 (14.8%) $P < 0.001$ †

\* N = 91.

† Statistical method employed: *t* test assuming unequal variance.

oxidase, peroxidase, and 4-aminophenazone. The first three compounds are widely used in laboratories interested in the investigation of cholinesterase problems in humans, but SDC has only recently been made amenable to such use. In this context, its advantages over other substrates are still a matter for debate.<sup>5,6</sup>

Our results are shown in table 1.

Dogs have lower cholinesterase activities than humans, whichever substrate is used, but the contrast is most marked when results obtained using SDC are compared.

As Professor Merin has pointed out, muscle relaxation in dogs is readily achieved following administration of 0.1–0.2 mg SDC/kg bodyweight, 10–20% of that required in humans. Such an observation can be reconciled with plasma cholinesterase activity only when the latter is measured using SDC. This emphasizes the importance of using such a method in the investigation of all animal species, but especially those in which experience with the use of SDC as a muscle relaxant is limited.

We believe that the failure until now to explain fully the differences in response of dogs and men to succinylcholine stems from the choice of techniques for cholinesterase analysis notable for their biochemical simplicity, rather than pharmacological relevance.

Anesthesiology  
68:472, 1988

*In Reply:*—I am very pleased to see the results of the plasma cholinesterase assays reported by Faye and Evans. Certainly their continued interest has resulted in clarification of the mechanism of the difference in kinetics for succinylcholine between humans and dogs. Appreciation of the difference is particularly important if investigators wish to recover their animals for use in chronic experiments. Elucidation of the mechanism behind these differences cannot help but advance experimental investigation. I thank Drs. Faye and Evans for their efforts.

SHERRY FAYE, M.Sc.  
Research Assistant

R. T. EVANS, M.C.B., PH.D.  
Consultant Biochemist  
Department of Chemical Pathology  
St. James's University Hospital  
Leeds LS9 7TF, U. K.

#### REFERENCES

1. Merin RG: Succinylcholine is different in humans than in dogs. *ANESTHESIOLOGY* 65:452, 1986
2. Evans RT, Wroe J: Is serum cholinesterase activity a predictor of succinylcholine sensitivity? An assessment of four methods. *Clin Chem* 24:1762–1766, 1978
3. Das PK, Liddell J: Value of butyrylthiocholine assay for identification of cholinesterase variants. *J Med Genet* 7:351–355, 1970
4. Kalow W, Lindsay HA: A comparison of optical and manometric methods for the assay of human serum cholinesterase. *Can J Biochem* 33:568–574, 1955
5. Faye SA, Evans RT: Is succinylcholine the substrate of choice for the measurement of cholinesterase activity? *Clin Chem* 32:1477–1480, 1986
6. Wakid NW, Baraka A: Succinylcholine as substrate in measurement of cholinesterase activity. *Clin Chem* 33:746–747, 1987

(Accepted for publication November 5, 1987.)

ROBERT G. MERIN, M.D.  
Professor of Anesthesiology  
Department of Anesthesiology  
The University of Texas  
Health Science Center at Houston  
6431 Fannin, 5.020 MSMB  
Houston, Texas 77030

(Accepted for publication November 5, 1987.)